These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36033123)

  • 21. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
    Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
    Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis.
    Vemuri D; Garuda BR; Gopi S; Kumar TS; Kumari UA
    Ann Indian Acad Neurol; 2020; 23(2):215-219. PubMed ID: 32189865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis.
    Feng X; Song Z; Wu M; Liu Y; Luo S; Zhao C; Zhang W
    Front Neurol; 2021; 12():725700. PubMed ID: 34925206
    [No Abstract]   [Full Text] [Related]  

  • 27. Efgartigimod: First Approval.
    Heo YA
    Drugs; 2022 Feb; 82(3):341-348. PubMed ID: 35179720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control.
    Konno S; Uchi T; Kihara H; Sugimoto H
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
    Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
    Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis.
    Chen R; Zhang N; Gao L; Zhong Y; Xu L; Liu H; Zheng Q; Li L
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1231-1240. PubMed ID: 34821184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis.
    Song Z; Zhang J; Meng J; Jiang G; Yan Z; Yang Y; Chen Z; You W; Wang Z; Chen G
    Front Pharmacol; 2021; 12():790834. PubMed ID: 35115936
    [No Abstract]   [Full Text] [Related]  

  • 32. The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds in Health Technology Assessment.
    Langley PC
    Pharmacy (Basel); 2020 Jul; 8(3):. PubMed ID: 32668706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efgartigimod alfa (Vyvgart) for myasthenia gravis.
    Med Lett Drugs Ther; 2022 Apr; 64(1648):62-63. PubMed ID: 35436776
    [No Abstract]   [Full Text] [Related]  

  • 35. Eculizumab versus rituximab in generalised myasthenia gravis.
    Nelke C; Schroeter CB; Stascheit F; Pawlitzki M; Regner-Nelke L; Huntemann N; Arat E; Öztürk M; Melzer N; Mergenthaler P; Gassa A; Stetefeld H; Schroeter M; Berger B; Totzeck A; Hagenacker T; Schreiber S; Vielhaber S; Hartung HP; Meisel A; Wiendl H; Meuth SG; Ruck T
    J Neurol Neurosurg Psychiatry; 2022 May; 93(5):548-554. PubMed ID: 35246490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
    Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
    Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: A meta-analysis.
    Frisaldi E; Shaibani A; Vollert J; Ferrero B; Carrino R; Ibraheem HD; Vase L; Benedetti F
    Muscle Nerve; 2019 Jun; 59(6):671-678. PubMed ID: 30883809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM).
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current pharmacotherapeutic options for myasthenia gravis.
    Barnett C; Tabasinejad R; Bril V
    Expert Opin Pharmacother; 2019 Dec; 20(18):2295-2303. PubMed ID: 31670984
    [No Abstract]   [Full Text] [Related]  

  • 40. Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
    de Meel RHP; Barnett C; Bril V; Tannemaat MR; Verschuuren JJGM
    J Neuromuscul Dis; 2020; 7(3):297-300. PubMed ID: 32250313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.